DexCom, Inc. (DXCM) Return on Invested Capital (ROIC): 16.61%
Is DexCom, Inc.’s return on invested capital (ROIC) high or low?
DexCom, Inc.'s return on invested capital (ROIC) of 16.61% is 73% above its 5-year average of 9.62%, near the high end of its 5-year range (5.30%–16.61%).
The return on invested capital (ROIC) for DexCom, Inc. (DXCM) is 16.61% as of Wednesday, June 10, 2026. It is above its 12-month average by 23.91% (13.40%).
DXCM Return on Invested Capital (ROIC) Chart
DXCM Average Return on Invested Capital (ROIC) Chart
DXCM Current vs Average Return on Invested Capital (ROIC) Chart
DXCM Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
16.61%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
13.40%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
11.07%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
9.62%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
0.14%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-13.87%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
-33.18%
CURRENT VS TTM AVG
+23.91%
CURRENT VS 3Y AVG
+49.98%
CURRENT VS 5Y AVG
+72.69%
CURRENT VS 10Y AVG
+11920.39%
CURRENT VS 15Y AVG
+219.79%
CURRENT VS 20Y AVG
+150.06%
DXCM Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $29.24B | 16.61% | 13.40% | 11.07% | 9.62% |
| Biogen Inc. (BIIB) | $29.00B | 6.62% | 7.71% | 8.64% | 10.90% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 8.23% | 8.41% | 8.23% | 6.99% |
| Medline Inc. (MDLN) | $30.90B | 5.69% | 6.03% | 3.95% | 3.95% |
| Veeva Systems Inc. (VEEV) | $26.73B | 9.48% | 9.25% | 9.54% | 11.31% |
| Centene Corporation (CNC) | $31.94B | -13.41% | -4.17% | -0.53% | 0.76% |
| Zoetis Inc. (ZTS) | $34.20B | 21.54% | 21.87% | 20.30% | 19.27% |
| Waters Corporation (WAT) | $23.83B | 17.57% | 18.00% | 20.73% | 22.79% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 35.46% | 38.26% | 37.51% | 36.01% |
| BioNTech SE (BNTX) | $21.81B | -3.14% | -4.79% | 9.55% | 20.42% |
Capital Efficiency
ROIC
16.6%
ROE
31.5%
DexCom, Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for DexCom, Inc. (DXCM)?
- The return on invested capital (ROIC) for DXCM stock is 16.61%.
- Is DexCom, Inc.'s return on invested capital (ROIC) high or low?
- DexCom, Inc.'s return on invested capital (ROIC) of 16.61% is 73% above its 5-year average of 9.62%, near the high end of its 5-year range (5.30%–16.61%).
- What is the TTM average return on invested capital (ROIC) for DexCom, Inc. (DXCM)?
- The TTM average return on invested capital (ROIC) for DXCM stock is 13.40%.
- What is the 3Y average return on invested capital (ROIC) for DexCom, Inc. (DXCM)?
- The 3Y average return on invested capital (ROIC) for DXCM stock is 11.07%.
- What is the 5Y average return on invested capital (ROIC) for DexCom, Inc. (DXCM)?
- The 5Y average return on invested capital (ROIC) for DXCM stock is 9.62%.
- What is the 10Y average return on invested capital (ROIC) for DexCom, Inc. (DXCM)?
- The 10Y average return on invested capital (ROIC) for DXCM stock is 0.14%.
- What is the 15Y average return on invested capital (ROIC) for DexCom, Inc. (DXCM)?
- The 15Y average return on invested capital (ROIC) for DXCM stock is -13.87%.
- What is the 20Y average return on invested capital (ROIC) for DexCom, Inc. (DXCM)?
- The 20Y average return on invested capital (ROIC) for DXCM stock is -33.18%.
DexCom, Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 16.61% |
| 2024-12-31 | 10.20% |
| 2023-12-31 | 9.63% |
| 2022-12-31 | 7.86% |
| 2021-12-31 | 5.30% |
| 2020-12-31 | 8.11% |
| 2019-12-31 | 6.74% |
| 2018-12-31 | -11.00% |
| 2017-12-31 | -5.55% |
| 2016-12-31 | -21.27% |
| 2015-12-31 | -25.11% |
| 2014-12-31 | -14.70% |
| 2013-12-31 | -31.21% |
| 2012-12-31 | -62.75% |
| 2011-12-31 | -42.32% |
| 2010-12-31 | -72.39% |
| 2009-12-31 | -157.76% |
| 2008-12-31 | -168.77% |
| 2007-12-31 | -66.50% |
| 2006-12-31 | -81.88% |
| 2005-12-31 | -0.07% |
| 2004-12-31 | -50.62% |
| 2003-12-31 | -51.48% |
| 2002-12-31 | 0.00% |
| 2001-12-31 | 0.00% |
| 2000-12-31 | 0.00% |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach